CCIA
RCUS icon

Campbell & Co Investment Adviser’s Arcus Biosciences RCUS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Buy
+9,408
New +$233K 0.02% 908
2025
Q2 		– Sell
-165,474
Closed -$1.3M – 1414
2025
Q1 		$1.3M Buy
+165,474
New +$1.92M 0.1% 326
2024
Q2 		– Sell
-37,496
Closed -$708K – 1294
2024
Q1 		$708K Sell
37,496
-25,398
-40% -$439K 0.06% 542
2023
Q4 		$1.2M Buy
+62,894
New +$1.01M 0.11% 307

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Campbell & Co Investment Adviser's RCUS Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 9,408 shares worth $290K. The stake represents 0.02% of the portfolio and ranks #908 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in RCUS as recently as Q1 2025.

Campbell & Co Investment Adviser first reported a position in RCUS in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.3M in Q1 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Campbell & Co Investment Adviser held 9,408 shares of Arcus Biosciences worth $290K as of Q2 2026.
  • Arcus Biosciences was a new Campbell & Co Investment Adviser position in Q2 2026.
  • Arcus Biosciences made up 0.02% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #908 holding.
  • Campbell & Co Investment Adviser first reported a position in Arcus Biosciences in Q4 2023 and has held it in 4 quarters since.
  • Campbell & Co Investment Adviser's Arcus Biosciences position peaked at $1.3M in Q1 2025.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.